Clinical Trials Logo

Carcinoma, Transitional Cell clinical trials

View clinical trials related to Carcinoma, Transitional Cell.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT02701023 No longer available - Clinical trials for Urothelial Carcinoma Ureteral Location

Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma

Start date: n/a
Phase: N/A
Study type: Expanded Access

The aim of this study is to evaluate the feasibility, safety, and efficacy of MitoGel in the treatment of UTUC in a human subject with low-grade UTUC which is endoscopically unresectable or rapidly recurring, and in whom nephrectomy would likely result in the need for permanent hemodialysis. The study drug would be obtained under the single patient access program approved by the FDA. The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks or once weekly for 6 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months. The total number of study patients is 1.